On May 15, 2025, a jury returned a verdict finding Amgen Inc. (“Amgen”) liable for antitrust violations and awarding Regeneron Pharmaceuticals, ...

A federal jury in Delaware has awarded Regeneron (NASDAQ:REGN) more than $400M in damages after finding that Amgen ...

In the long-running feud between Regeneron and Amgen around the companies’ competing PCSK9 cholesterol meds, Regeneron has eked out another legal win over its rival. | A federal jury in Delaware has ...

Regeneron Pharmaceuticals Inc.'s victory against Amgen Inc. over anticompetitive drug bundling reinforces the necessity for ...

A federal jury found Amgen liable for violating antitrust and tort laws. Elsewhere, Allogene and Kyverna trimmed staff and ...

Morning! Today we start with some breaking newss: Novo Nordisk’s CEO is stepping down. We also discuss a new, tailored CRISPR treatment for an infant with a deadly disease, how Amgen owes Regeneron ...

Regeneron Pharmaceuticals won $406.8 million in damages for a lawsuit claiming Amgen violated antitrust and tort laws. A jury in a Delaware court found that Amgen violated certain laws, and gave ...

Amgen prevented Regeneron from competing on a level playing field and unfairly denied patients access to Praluent. This anticompetitive practice shut out an innovative therapy from the PCSK9 ...

Amgen (NasdaqGS:AMGN) recently faced a legal setback, with a U.S. District Court jury finding the company liable for ...

A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 million for ...

A federal jury in Delaware has awarded Regeneron (NASDAQ:REGN) more than $400M in damages after finding that Amgen (NASDAQ:AMGN) violated U.S. antitrust laws by forcing pharmacy benefit managers ...